Trial Condition(s):
Hepatocellular carcinoma, Treatment of advanced renal cell carcinoma
BAY43-9006/sorafenib+gem+cisplatin Phase I combination study
Bayer Identifier:
12386
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
20
Trial Dates
Phase
1
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
N/A
Where to Participate
Loading...
Locations
Status
| Locations | Status | |
|---|---|---|
Locations Marienhospital Herne Universitätsklinik Herne, Germany, 44625 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
For details, please refer to trial results
Additional Information
Copyright © Bayer
Powered by
